Oncolytics Biotech announced that its investigational immunotherapy pelareorep showed a median response duration of 19.5 months in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer patients, significantly exceeding the historical 4-6 month benchmark. The combination therapy also achieved a 33% objective response rate, tripling standard care outcomes. The company is engaging with the FDA to pursue accelerated approval based on these promising results and is currently enrolling patients in a Phase 2 trial. This development addresses a critical unmet need in a difficult-to-treat cancer population, potentially offering a new effective treatment option.
Perplexity AI CEO Aravind Srinivas shared lessons from Nvidia's Jensen Huang and Tesla's Elon Musk, highlighting Huang's mindset of running Nvidia as if it could fail within 30 days despite its $5 trillion valuation and advanced technology. Srinivas ...
Meta Platforms introduced an AI-powered feature called "AI Mode" within Facebook Search, which uses Meta's AI model Muse Spark to provide answers from public content rather than traditional search results. This innovation could generate over $10 bill...
Cuprina Holdings shares surged 111.84% intraday following FDA 510(k) clearance for its MEDIFLY Maggots wound care product, the first maggot debridement therapy using Lucilia cuprina species approved in the U.S. The product treats non-healing necrotic...
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
